Loading…

The EPICURE study: a pilot prospective cohort study of heterogeneous and massive data integration in metastatic breast cancer patients

Breast cancer is the most common cancer in women and the first cancer concerning mortality. Metastatic breast cancer remains a disease with a poor prognosis and about 30% of women diagnosed with an early stage will have a secondary progression. Metastatic breast cancer is an incurable disease despit...

Full description

Saved in:
Bibliographic Details
Published in:BMC cancer 2021-03, Vol.21 (1), p.333-333, Article 333
Main Authors: Colombié, Mathilde, Jézéquel, Pascal, Rubeaux, Mathieu, Frenel, Jean-Sébastien, Bigot, Frédéric, Seegers, Valérie, Campone, Mario
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c665t-3ddf5082782340c0749a1f691e239fc1e630179c95ee876ce124419f6477167b3
cites cdi_FETCH-LOGICAL-c665t-3ddf5082782340c0749a1f691e239fc1e630179c95ee876ce124419f6477167b3
container_end_page 333
container_issue 1
container_start_page 333
container_title BMC cancer
container_volume 21
creator Colombié, Mathilde
Jézéquel, Pascal
Rubeaux, Mathieu
Frenel, Jean-Sébastien
Bigot, Frédéric
Seegers, Valérie
Campone, Mario
description Breast cancer is the most common cancer in women and the first cancer concerning mortality. Metastatic breast cancer remains a disease with a poor prognosis and about 30% of women diagnosed with an early stage will have a secondary progression. Metastatic breast cancer is an incurable disease despite significant therapeutic advances in both supportive cares and targeted specific therapies. In the management of a metastatic patient, each clinician follows a highly complex and strictly personal decision making process. It is based on a number of objective and subjective parameters which guides therapeutic choice in the most individualized or adapted manner. The main objective is to integrate massive and heterogeneous data concerning the patient's environment, personal and familial history, clinical and biological data, imaging, histological results (with multi-omics data), and microbiota analysis. These characteristics are multiple and in dynamic interaction overtime. With the help of mathematical units with biological competences and scientific collaborations, our project is to improve the comprehension of treatment response, based on health clinical and molecular heterogeneous big data investigation. Our project is to prove feasibility of creation of a clinico-biological database prospectively by collecting epidemiological, socio-economic, clinical, biological, pathological, multi-omic data and to identify characteristics related to the overall survival status before treatment and within 15 years after treatment start from a cohort of 300 patients with a metastatic breast cancer treated in the institution. ClinicalTrials.gov identifier (NCT number): NCT03958136 . Registration 21st of May, 2019; retrospectively registered.
doi_str_mv 10.1186/s12885-021-08060-8
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_a8460bd3abbf4701b7f1fdd98a7d5b53</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A657274795</galeid><doaj_id>oai_doaj_org_article_a8460bd3abbf4701b7f1fdd98a7d5b53</doaj_id><sourcerecordid>A657274795</sourcerecordid><originalsourceid>FETCH-LOGICAL-c665t-3ddf5082782340c0749a1f691e239fc1e630179c95ee876ce124419f6477167b3</originalsourceid><addsrcrecordid>eNptk99rFDEQxxdRbK3-Az5IQBAFtyabzS8fhHKc9qCg1PY5ZLOzt1t2N9skW-w_4N9t7q7WXpE8ZDL5zDeZZCbLXhN8TIjknwIppGQ5LkiOJeY4l0-yQ1IKkhclFk8f2AfZixCuMCZCYvk8O6BUSMUpO8x-X7SAlj9Wi8vzJQpxrm8_I4OmrncRTd6FCWzsbgBZ1zofdwRyDWohgndrGMHNAZmxRoMJYUPWJhrUjRHW3sTOjclGA0QTYlpaVHlIJrJmtODRlHwwxvAye9aYPsCru_kou_y6vFic5mffv60WJ2e55ZzFnNZ1w7AshCxoiS0WpTKk4YpAQVVjCXCaclRWMQApuAVSlCVRDS-FIFxU9Chb7XRrZ6705LvB-FvtTKe3DufX2vh0zR60kSXHVU1NVTWlwKQSDWnqWkkjalYxmrS-7LSmuRqgtikPb_o90f2dsWv12t1oiQkhTCWBjzuB9lHY6cmZ7sYAftCYFkSykt2QhL-_O8-76xlC1EMXLPS92X6CLhgWgmJVlAl9-wi9crMf08smKlUFp0rJf9TapHy7sXHpmnYjqk84E4UohWKJOv4PlUYNQ2fdCE2X_HsBH_YCEhPhV1ybOQS9-nm-z757wLZg-tgG18-bwgn7YLEDbSrK4KG5fzCC9aYb9K4bdOoGve0GvUnwzcMfug_5W_70D_NjAwo</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2514763998</pqid></control><display><type>article</type><title>The EPICURE study: a pilot prospective cohort study of heterogeneous and massive data integration in metastatic breast cancer patients</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Colombié, Mathilde ; Jézéquel, Pascal ; Rubeaux, Mathieu ; Frenel, Jean-Sébastien ; Bigot, Frédéric ; Seegers, Valérie ; Campone, Mario</creator><creatorcontrib>Colombié, Mathilde ; Jézéquel, Pascal ; Rubeaux, Mathieu ; Frenel, Jean-Sébastien ; Bigot, Frédéric ; Seegers, Valérie ; Campone, Mario</creatorcontrib><description>Breast cancer is the most common cancer in women and the first cancer concerning mortality. Metastatic breast cancer remains a disease with a poor prognosis and about 30% of women diagnosed with an early stage will have a secondary progression. Metastatic breast cancer is an incurable disease despite significant therapeutic advances in both supportive cares and targeted specific therapies. In the management of a metastatic patient, each clinician follows a highly complex and strictly personal decision making process. It is based on a number of objective and subjective parameters which guides therapeutic choice in the most individualized or adapted manner. The main objective is to integrate massive and heterogeneous data concerning the patient's environment, personal and familial history, clinical and biological data, imaging, histological results (with multi-omics data), and microbiota analysis. These characteristics are multiple and in dynamic interaction overtime. With the help of mathematical units with biological competences and scientific collaborations, our project is to improve the comprehension of treatment response, based on health clinical and molecular heterogeneous big data investigation. Our project is to prove feasibility of creation of a clinico-biological database prospectively by collecting epidemiological, socio-economic, clinical, biological, pathological, multi-omic data and to identify characteristics related to the overall survival status before treatment and within 15 years after treatment start from a cohort of 300 patients with a metastatic breast cancer treated in the institution. ClinicalTrials.gov identifier (NCT number): NCT03958136 . Registration 21st of May, 2019; retrospectively registered.</description><identifier>ISSN: 1471-2407</identifier><identifier>EISSN: 1471-2407</identifier><identifier>DOI: 10.1186/s12885-021-08060-8</identifier><identifier>PMID: 33789635</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Algorithms ; Breast cancer ; Breast Neoplasms - epidemiology ; Cancer therapies ; Care and treatment ; Cohort ; Cohort analysis ; Cohort Studies ; Collection ; Complications and side effects ; Decision making ; Epidemiology ; Estrogens ; Evaluation ; Female ; Heterogeneous ; Humans ; Hypotheses ; Life Sciences ; Medical prognosis ; Metastases ; Metastasis ; Metastatic breast cancer ; Microbiota ; Mortality ; Multi-omics data ; Neoplasm Metastasis ; Patients ; Pilot Projects ; Practice guidelines (Medicine) ; Prediction ; Prospective Studies ; Quality of life ; Quality of Life - psychology ; Study Protocol ; Womens health</subject><ispartof>BMC cancer, 2021-03, Vol.21 (1), p.333-333, Article 333</ispartof><rights>COPYRIGHT 2021 BioMed Central Ltd.</rights><rights>2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><rights>The Author(s) 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c665t-3ddf5082782340c0749a1f691e239fc1e630179c95ee876ce124419f6477167b3</citedby><cites>FETCH-LOGICAL-c665t-3ddf5082782340c0749a1f691e239fc1e630179c95ee876ce124419f6477167b3</cites><orcidid>0000-0001-9187-1394 ; 0000-0002-5273-0561 ; 0000-0002-5196-5908</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8011159/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2514763998?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33789635$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://inserm.hal.science/inserm-03218545$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Colombié, Mathilde</creatorcontrib><creatorcontrib>Jézéquel, Pascal</creatorcontrib><creatorcontrib>Rubeaux, Mathieu</creatorcontrib><creatorcontrib>Frenel, Jean-Sébastien</creatorcontrib><creatorcontrib>Bigot, Frédéric</creatorcontrib><creatorcontrib>Seegers, Valérie</creatorcontrib><creatorcontrib>Campone, Mario</creatorcontrib><title>The EPICURE study: a pilot prospective cohort study of heterogeneous and massive data integration in metastatic breast cancer patients</title><title>BMC cancer</title><addtitle>BMC Cancer</addtitle><description>Breast cancer is the most common cancer in women and the first cancer concerning mortality. Metastatic breast cancer remains a disease with a poor prognosis and about 30% of women diagnosed with an early stage will have a secondary progression. Metastatic breast cancer is an incurable disease despite significant therapeutic advances in both supportive cares and targeted specific therapies. In the management of a metastatic patient, each clinician follows a highly complex and strictly personal decision making process. It is based on a number of objective and subjective parameters which guides therapeutic choice in the most individualized or adapted manner. The main objective is to integrate massive and heterogeneous data concerning the patient's environment, personal and familial history, clinical and biological data, imaging, histological results (with multi-omics data), and microbiota analysis. These characteristics are multiple and in dynamic interaction overtime. With the help of mathematical units with biological competences and scientific collaborations, our project is to improve the comprehension of treatment response, based on health clinical and molecular heterogeneous big data investigation. Our project is to prove feasibility of creation of a clinico-biological database prospectively by collecting epidemiological, socio-economic, clinical, biological, pathological, multi-omic data and to identify characteristics related to the overall survival status before treatment and within 15 years after treatment start from a cohort of 300 patients with a metastatic breast cancer treated in the institution. ClinicalTrials.gov identifier (NCT number): NCT03958136 . Registration 21st of May, 2019; retrospectively registered.</description><subject>Algorithms</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - epidemiology</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Cohort</subject><subject>Cohort analysis</subject><subject>Cohort Studies</subject><subject>Collection</subject><subject>Complications and side effects</subject><subject>Decision making</subject><subject>Epidemiology</subject><subject>Estrogens</subject><subject>Evaluation</subject><subject>Female</subject><subject>Heterogeneous</subject><subject>Humans</subject><subject>Hypotheses</subject><subject>Life Sciences</subject><subject>Medical prognosis</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Metastatic breast cancer</subject><subject>Microbiota</subject><subject>Mortality</subject><subject>Multi-omics data</subject><subject>Neoplasm Metastasis</subject><subject>Patients</subject><subject>Pilot Projects</subject><subject>Practice guidelines (Medicine)</subject><subject>Prediction</subject><subject>Prospective Studies</subject><subject>Quality of life</subject><subject>Quality of Life - psychology</subject><subject>Study Protocol</subject><subject>Womens health</subject><issn>1471-2407</issn><issn>1471-2407</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptk99rFDEQxxdRbK3-Az5IQBAFtyabzS8fhHKc9qCg1PY5ZLOzt1t2N9skW-w_4N9t7q7WXpE8ZDL5zDeZZCbLXhN8TIjknwIppGQ5LkiOJeY4l0-yQ1IKkhclFk8f2AfZixCuMCZCYvk8O6BUSMUpO8x-X7SAlj9Wi8vzJQpxrm8_I4OmrncRTd6FCWzsbgBZ1zofdwRyDWohgndrGMHNAZmxRoMJYUPWJhrUjRHW3sTOjclGA0QTYlpaVHlIJrJmtODRlHwwxvAye9aYPsCru_kou_y6vFic5mffv60WJ2e55ZzFnNZ1w7AshCxoiS0WpTKk4YpAQVVjCXCaclRWMQApuAVSlCVRDS-FIFxU9Chb7XRrZ6705LvB-FvtTKe3DufX2vh0zR60kSXHVU1NVTWlwKQSDWnqWkkjalYxmrS-7LSmuRqgtikPb_o90f2dsWv12t1oiQkhTCWBjzuB9lHY6cmZ7sYAftCYFkSykt2QhL-_O8-76xlC1EMXLPS92X6CLhgWgmJVlAl9-wi9crMf08smKlUFp0rJf9TapHy7sXHpmnYjqk84E4UohWKJOv4PlUYNQ2fdCE2X_HsBH_YCEhPhV1ybOQS9-nm-z757wLZg-tgG18-bwgn7YLEDbSrK4KG5fzCC9aYb9K4bdOoGve0GvUnwzcMfug_5W_70D_NjAwo</recordid><startdate>20210331</startdate><enddate>20210331</enddate><creator>Colombié, Mathilde</creator><creator>Jézéquel, Pascal</creator><creator>Rubeaux, Mathieu</creator><creator>Frenel, Jean-Sébastien</creator><creator>Bigot, Frédéric</creator><creator>Seegers, Valérie</creator><creator>Campone, Mario</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ISR</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-9187-1394</orcidid><orcidid>https://orcid.org/0000-0002-5273-0561</orcidid><orcidid>https://orcid.org/0000-0002-5196-5908</orcidid></search><sort><creationdate>20210331</creationdate><title>The EPICURE study: a pilot prospective cohort study of heterogeneous and massive data integration in metastatic breast cancer patients</title><author>Colombié, Mathilde ; Jézéquel, Pascal ; Rubeaux, Mathieu ; Frenel, Jean-Sébastien ; Bigot, Frédéric ; Seegers, Valérie ; Campone, Mario</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c665t-3ddf5082782340c0749a1f691e239fc1e630179c95ee876ce124419f6477167b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Algorithms</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - epidemiology</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Cohort</topic><topic>Cohort analysis</topic><topic>Cohort Studies</topic><topic>Collection</topic><topic>Complications and side effects</topic><topic>Decision making</topic><topic>Epidemiology</topic><topic>Estrogens</topic><topic>Evaluation</topic><topic>Female</topic><topic>Heterogeneous</topic><topic>Humans</topic><topic>Hypotheses</topic><topic>Life Sciences</topic><topic>Medical prognosis</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Metastatic breast cancer</topic><topic>Microbiota</topic><topic>Mortality</topic><topic>Multi-omics data</topic><topic>Neoplasm Metastasis</topic><topic>Patients</topic><topic>Pilot Projects</topic><topic>Practice guidelines (Medicine)</topic><topic>Prediction</topic><topic>Prospective Studies</topic><topic>Quality of life</topic><topic>Quality of Life - psychology</topic><topic>Study Protocol</topic><topic>Womens health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Colombié, Mathilde</creatorcontrib><creatorcontrib>Jézéquel, Pascal</creatorcontrib><creatorcontrib>Rubeaux, Mathieu</creatorcontrib><creatorcontrib>Frenel, Jean-Sébastien</creatorcontrib><creatorcontrib>Bigot, Frédéric</creatorcontrib><creatorcontrib>Seegers, Valérie</creatorcontrib><creatorcontrib>Campone, Mario</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>BMC cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Colombié, Mathilde</au><au>Jézéquel, Pascal</au><au>Rubeaux, Mathieu</au><au>Frenel, Jean-Sébastien</au><au>Bigot, Frédéric</au><au>Seegers, Valérie</au><au>Campone, Mario</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The EPICURE study: a pilot prospective cohort study of heterogeneous and massive data integration in metastatic breast cancer patients</atitle><jtitle>BMC cancer</jtitle><addtitle>BMC Cancer</addtitle><date>2021-03-31</date><risdate>2021</risdate><volume>21</volume><issue>1</issue><spage>333</spage><epage>333</epage><pages>333-333</pages><artnum>333</artnum><issn>1471-2407</issn><eissn>1471-2407</eissn><abstract>Breast cancer is the most common cancer in women and the first cancer concerning mortality. Metastatic breast cancer remains a disease with a poor prognosis and about 30% of women diagnosed with an early stage will have a secondary progression. Metastatic breast cancer is an incurable disease despite significant therapeutic advances in both supportive cares and targeted specific therapies. In the management of a metastatic patient, each clinician follows a highly complex and strictly personal decision making process. It is based on a number of objective and subjective parameters which guides therapeutic choice in the most individualized or adapted manner. The main objective is to integrate massive and heterogeneous data concerning the patient's environment, personal and familial history, clinical and biological data, imaging, histological results (with multi-omics data), and microbiota analysis. These characteristics are multiple and in dynamic interaction overtime. With the help of mathematical units with biological competences and scientific collaborations, our project is to improve the comprehension of treatment response, based on health clinical and molecular heterogeneous big data investigation. Our project is to prove feasibility of creation of a clinico-biological database prospectively by collecting epidemiological, socio-economic, clinical, biological, pathological, multi-omic data and to identify characteristics related to the overall survival status before treatment and within 15 years after treatment start from a cohort of 300 patients with a metastatic breast cancer treated in the institution. ClinicalTrials.gov identifier (NCT number): NCT03958136 . Registration 21st of May, 2019; retrospectively registered.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>33789635</pmid><doi>10.1186/s12885-021-08060-8</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0001-9187-1394</orcidid><orcidid>https://orcid.org/0000-0002-5273-0561</orcidid><orcidid>https://orcid.org/0000-0002-5196-5908</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1471-2407
ispartof BMC cancer, 2021-03, Vol.21 (1), p.333-333, Article 333
issn 1471-2407
1471-2407
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_a8460bd3abbf4701b7f1fdd98a7d5b53
source Publicly Available Content Database; PubMed Central
subjects Algorithms
Breast cancer
Breast Neoplasms - epidemiology
Cancer therapies
Care and treatment
Cohort
Cohort analysis
Cohort Studies
Collection
Complications and side effects
Decision making
Epidemiology
Estrogens
Evaluation
Female
Heterogeneous
Humans
Hypotheses
Life Sciences
Medical prognosis
Metastases
Metastasis
Metastatic breast cancer
Microbiota
Mortality
Multi-omics data
Neoplasm Metastasis
Patients
Pilot Projects
Practice guidelines (Medicine)
Prediction
Prospective Studies
Quality of life
Quality of Life - psychology
Study Protocol
Womens health
title The EPICURE study: a pilot prospective cohort study of heterogeneous and massive data integration in metastatic breast cancer patients
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T16%3A12%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20EPICURE%20study:%20a%20pilot%20prospective%20cohort%20study%20of%20heterogeneous%20and%20massive%20data%20integration%20in%20metastatic%20breast%20cancer%20patients&rft.jtitle=BMC%20cancer&rft.au=Colombi%C3%A9,%20Mathilde&rft.date=2021-03-31&rft.volume=21&rft.issue=1&rft.spage=333&rft.epage=333&rft.pages=333-333&rft.artnum=333&rft.issn=1471-2407&rft.eissn=1471-2407&rft_id=info:doi/10.1186/s12885-021-08060-8&rft_dat=%3Cgale_doaj_%3EA657274795%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c665t-3ddf5082782340c0749a1f691e239fc1e630179c95ee876ce124419f6477167b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2514763998&rft_id=info:pmid/33789635&rft_galeid=A657274795&rfr_iscdi=true